DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-460

Bristol-Myers Squibb, Inc.
Attention: Warren C. Randolph
Director, Regulatory Science
P.O. Box 4000
Princeton, NJ 08543-4000

Dear Mr. Randolph:

Please refer to your new drug application (NDA) submitted and received December 21, 2001under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Metaglip™ (glipizide/metformin HCl) Tablets 2.5 mg/250 mg, 2.5 mg/500 mg, and 5 mg/500 mg.

We acknowledge receipt of your amendments dated:

January 23, 2002	July 10, 2002
February 1, 2002	July 30, 2002
April 25, 2002	August 15, 2002
May 14, 2002	October 17, 2002
June 26, 2002	October 21, 2002

This new drug application provides for the use of Metaglip™ (glipizide/metformin HCl) Tablets as:

1. Initial therapy, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes whose hyperglycemia cannot be satisfactorily managed with diet and exercise alone.
2. Second-line therapy when diet, exercise, and first-line treatment with a sulfonylurea or metformin do not result in adequate glycemic control in patients with type 2 diabetes.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed submitted labeling (physician and patient package inserts and immediate container and carton labels submitted October 18, 2002). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, designate this

submission "**FPL for approved NDA 21-460**." Approval of this submission by FDA is not required before the labeling is used.

We remind you of your postmarketing study commitment in your submission dated October 17, 2002.

Postmarketing Commitment:

Description: To evaluate multi-point dissolution data at pH 6.8 and pH7.5 in parallel for Metaglip™ (glipizide/metformin HCl) Tablets of each strength (2.5 mg/250 mg, 2.5 mg/500 mg, and 5 mg/500 mg) at release and on long term stability, representative of controlled and stressed conditions.

Protocol Submission:	Within 1 month of the date of this letter
Study Start:	Within 2 months of the date of this letter
Final Report Submission:	Within 6 months of the date of this letter

Submit clinical protocols to your IND for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to these postmarketing study commitments must be prominently labeled "**Postmarketing Study Protocol", "Postmarketing Study Final Report", or "Postmarketing Study Correspondence."**

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the physician and patient package inserts directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call James Cross, Regulatory Project Manager, at (301) 827-6381.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products, HFD-510
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

David Orloff

10/21/02 03:18:34 PM